GSK Relative Valuation - GlaxoSmithKline PLC - Alpha Spread
G

GlaxoSmithKline PLC
NYSE:GSK

Watchlist Manager
GlaxoSmithKline PLC
NYSE:GSK
Watchlist
Price: 38.82 USD 1.17% Market Closed
Market Cap: 79.2B USD
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

Relative Value

The Relative Value of one GSK stock under the Base Case scenario is 65.16 USD. Compared to the current market price of 38.82 USD, GlaxoSmithKline PLC is Undervalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GSK Relative Value
Base Case
65.16 USD
Undervaluation 40%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
55
vs Industry
52
Median 3Y
2
Median 5Y
2
Industry
2.6
Forward
1.9
vs History
12
vs Industry
31
Median 3Y
13.1
Median 5Y
12
Industry
22.9
Forward
9
vs History
36
vs Industry
39
Median 3Y
8.3
Median 5Y
7.6
Industry
17.6
vs History
vs Industry
12
Median 3Y
26.4
Median 5Y
19.8
Industry
25.2
vs History
63
vs Industry
17
Median 3Y
4.5
Median 5Y
4.4
Industry
2.2
vs History
73
vs Industry
44
Median 3Y
2.4
Median 5Y
2.4
Industry
2.7
Forward
2.2
vs History
85
vs Industry
57
Median 3Y
3.4
Median 5Y
3.4
Industry
5.4
vs History
80
vs Industry
40
Median 3Y
7
Median 5Y
7.1
Industry
13.9
Forward
6.6
vs History
53
vs Industry
37
Median 3Y
9.7
Median 5Y
9.5
Industry
17.3
Forward
8
vs History
49
vs Industry
37
Median 3Y
9.9
Median 5Y
9.5
Industry
16.1
vs History
47
vs Industry
25
Median 3Y
15.2
Median 5Y
13.1
Industry
18.8
vs History
33
vs Industry
39
Median 3Y
1.7
Median 5Y
1.4
Industry
2

Multiples Across Competitors

GSK Competitors Multiples
GlaxoSmithKline PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
GlaxoSmithKline PLC
NYSE:GSK
79.2B USD 1.9 15 6.7 9.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
843.2B USD 21.7 114.8 57.4 64.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.3 38.2 25.5 29.2
US
Johnson & Johnson
NYSE:JNJ
385.8B USD 4.5 10.1 12.4 16.1
US
Merck & Co Inc
NYSE:MRK
278.3B USD 4.5 20.3 13.7 16.8
CH
Roche Holding AG
SIX:ROG
206.1B CHF 3.5 17.9 10.1 12
UK
AstraZeneca PLC
NASDAQ:AZN
240.2B USD 4.9 37.3 17.1 25.6
CH
Novartis AG
SIX:NOVN
191.2B CHF 4.6 13.8 10.9 16.1
US
Pfizer Inc
NYSE:PFE
162B USD 2.9 -62.4 12.6 20.4
P/E Multiple
Earnings Growth
UK
G
GlaxoSmithKline PLC
NYSE:GSK
Average P/E: 33.4
15
66%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
114.8
425%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
38.2
90%
US
Johnson & Johnson
NYSE:JNJ
10.1
-22%
US
Merck & Co Inc
NYSE:MRK
20.3
7 419%
CH
Roche Holding AG
SIX:ROG
17.9
30%
UK
A
AstraZeneca PLC
NASDAQ:AZN
37.3
175%
CH
Novartis AG
SIX:NOVN
13.8
19%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -62.4
712%

See Also

Discover More
Back to Top